Citadel Advisors
CTNM

Citadel Advisors’s Contineum Therapeutics CTNM Stock Holding History

Citadel Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.57M Buy
+350,200
New +$4.7M ﹤0.01% 4492
2025
Q3 		– Sell
-16,489
Closed -$65.5K – 14370
2025
Q2 		$65.5K Buy
+16,489
New +$71.7K ﹤0.01% 11629
2024
Q3 		– Sell
-127,785
Closed -$2.25M – 15434
2024
Q2 		$2.25M Buy
+127,785
New +$2.06M ﹤0.01% 5096

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's CTNM Position: Q1 2026 in Review

Citadel Advisors opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 350,200 shares worth $4.57M. The stake represents ﹤0.01% of the portfolio and ranks #4492 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CTNM as recently as Q2 2025.

Citadel Advisors first reported a position in CTNM in Q2 2024 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Citadel Advisors held 350,200 shares of Contineum Therapeutics worth $4.57M as of Q1 2026.
  • Contineum Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4492 holding.
  • Citadel Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.